ArticleFrontiers in aging2026
Rare and novel genetic variants in sporadic and familial Alzheimer's disease: insights from the first Saudi cohort.
Article in Frontiers in aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alzheimer's disease (AD) is a complex brain disorder that is greatly affected by genetics. Next-generation sequencing (NGS) has facilitated the discovery of rare variants in new genes that may be linked to AD in different populations. However, we still know very little about the genetic makeup of AD in Saudi Arabia and other Arab populations. Objectives: This study aims to explore rare variants that are predicted to be deleterious in a group of 64 Saudi patients diagnosed with sporadic and familial Alzheimer's disease (AD). These patients previously tested negative for mutations in genes known to cause AD and were genotyped for Methods: We performed whole-exome sequencing (WES) on the Ion Proton platform. Then, we used our internal process for filtering, validating, and prioritizing variants. Results: Using stringent selection criteria, we identified 107 rare candidate variants with potential functional relevance. Of these, 26 (24.3%) were novel, while the remaining variants had been previously reported in public databases. Among these candidates, 33 were connected to AD, 28 to both AD and other neurodegenerative disorders (OND), 34 to OND-related functions, and 11 to broader processes like aging, inflammation, and neuronal regulation. We found rare missense variants in genes involved in important processes related to Alzheimer's disease. These processes include mainly Aβ and Tau pathology, kinase signaling, stress response, and neuroinflammation. Conclusion: Our analysis reveals diverse genetic contributors to Alzheimer's disease in a population that remains largely underrepresented in genomic studies. We identified candidate variants in 53% of the patients, highlighting the value of expanding AD genetics research to non-European populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.